3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow Cancer Targeted Technology: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer CTT1403, CTT1057, 68Ga-PSMA-11 - Prostate Cancer | Phase 1 | Completed | Cancer Targeted Technology | 17 | 2019-04-01 | 2024-03-21 |
| CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma CTT1057 - Renal Cell Carcinoma | Phase 1 | Completed | Cancer Targeted Technology | 4 | 2018-01-01 | 2019-04-22 |
| A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057 CTT1057, Prostatectomy - Prostate Cancer | Phase 1 | Completed | Cancer Targeted Technology | 20 | 2016-09-01 | 2017-11-06 |
Prostatic Neoplasms (2) · Carcinoma, Renal Cell (1) · Kidney Neoplasms (1) · Prostatic Hyperplasia (1)
Prostatectomy (1) · gallium 68 PSMA-11 (1)
United States (3)
Beatrice Langton-Webster, PhD (3) · Rahul Aggarwal, MD (1)
R44CA239461 (1)